Published in Cell Cycle on May 28, 2007
Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 2.34
A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle (2011) 2.13
A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst (2012) 2.07
A planarian p53 homolog regulates proliferation and self-renewal in adult stem cell lineages. Development (2010) 1.83
Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids (2010) 1.82
DNA replication stress, genome instability and aging. Nucleic Acids Res (2007) 1.80
Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics (2008) 1.31
Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. J Clin Invest (2007) 1.30
The mitochondrial death pathway: a promising therapeutic target in diseases. J Cell Mol Med (2009) 1.30
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci U S A (2009) 1.25
Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS One (2009) 1.22
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer (2009) 1.22
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene (2011) 1.20
Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene (2008) 1.20
Association of Mycoplasma hominis infection with prostate cancer. Oncotarget (2011) 1.19
P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer (2011) 1.18
Dysregulation of RNA polymerase I transcription during disease. Biochim Biophys Acta (2012) 1.16
Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res (2009) 1.13
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer (2010) 1.11
Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res (2010) 1.09
SnoN functions as a tumour suppressor by inducing premature senescence. EMBO J (2009) 1.09
Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol (2010) 1.09
Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia (2011) 1.08
DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene (2012) 1.07
New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital (2013) 1.07
Crucial roles for interactions between MLL3/4 and INI1 in nuclear receptor transactivation. Mol Endocrinol (2009) 1.06
An updated overview of HPV-associated head and neck carcinomas. Oncotarget (2014) 1.06
Response of heterogeneous ribonuclear proteins (hnRNP) to ionising radiation and their involvement in DNA damage repair. Int J Radiat Biol (2009) 1.05
Ionizing radiation-induced responses in human cells with differing TP53 status. Int J Mol Sci (2013) 1.04
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res (2011) 1.04
Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol (2011) 1.03
Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol (2015) 1.03
A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Oncogene (2011) 1.00
Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci (2014) 0.98
SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage. Cell Signal (2008) 0.98
p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG. Cancer Lett (2010) 0.96
Doubles game: Src-Stat3 versus p53-PTEN in cellular migration and invasion. Mol Cell Biol (2010) 0.95
JDP2 (Jun Dimerization Protein 2)-deficient mouse embryonic fibroblasts are resistant to replicative senescence. J Biol Chem (2009) 0.93
Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci (2013) 0.93
Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res (2009) 0.92
Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis (2008) 0.92
Predicting transcriptional activity of multiple site p53 mutants based on hybrid properties. PLoS One (2011) 0.90
Prototypes of newly conceived inorganic and biological sensors for health and environmental applications. Sensors (Basel) (2012) 0.89
Suv4-20h abrogation enhances telomere elongation during reprogramming and confers a higher tumorigenic potential to iPS cells. PLoS One (2011) 0.88
Loss of p19(Arf) facilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53-dependent and independent mechanisms. PLoS One (2010) 0.88
p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol (2013) 0.86
Characterization of the p53 response to oncogene-induced senescence. PLoS One (2008) 0.86
Radiation Sensitivity and Tumor Susceptibility in ATM Phospho-Mutant ATF2 Mice. Genes Cancer (2010) 0.85
Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. Carcinogenesis (2012) 0.84
Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo. Radiat Oncol (2014) 0.83
p53-mediated control of gene expression via mRNA translation during Endoplasmic Reticulum stress. Cell Cycle (2015) 0.82
p53 and mitochondrial DNA: their role in mitochondrial homeostasis and toxicity of antiretrovirals. Am J Pathol (2012) 0.82
p53 regulation of podosome formation and cellular invasion in vascular smooth muscle cells. Cell Adh Migr (2011) 0.82
Collateral damage: insights into bacterial mechanisms that predispose host cells to cancer. Nat Rev Microbiol (2017) 0.81
Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure. Cardiovasc Res (2010) 0.81
Role of Gadd45a in Wip1-dependent regulation of intestinal tumorigenesis. Cell Death Differ (2012) 0.81
Alteration of WWOX in human cancer: a clinical view. Exp Biol Med (Maywood) (2015) 0.80
Senescence in adipose-derived stem cells and its implications in nerve regeneration. Neural Regen Res (2014) 0.80
Elevated ornithine decarboxylase levels activate ataxia telangiectasia mutated-DNA damage signaling in normal keratinocytes. Cancer Res (2008) 0.80
The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget (2016) 0.79
DNA damage and DNA damage responses in THP-1 monocytes after exposure to spores of either Stachybotrys chartarum or Aspergillus versicolor or to T-2 toxin. Toxicol Sci (2010) 0.79
p53 mutations associated with aging-related rise in cancer incidence rates. Cell Cycle (2013) 0.79
Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses. Toxicol Sci (2012) 0.79
Acetylation of lysine 382 and phosphorylation of serine 392 in p53 modulate the interaction between p53 and MDC1 in vitro. PLoS One (2013) 0.79
Experimental evolution reveals that high relatedness protects multicellular cooperation from cheaters. Nat Commun (2016) 0.79
Therapeutic strategies for head and neck cancer based on p53 status. Exp Ther Med (2012) 0.78
How do K-RAS-activated cells evade cellular defense mechanisms? Oncogene (2015) 0.78
Mitochondrial matrix P53 sensitizes cells to oxidative stress. Mitochondrion (2013) 0.78
The prognostic significance of p53 expression in gastric cancer: a meta-analysis. J Cancer Res Clin Oncol (2014) 0.78
Alterations of tumor-related genes do not exactly match the histopathological grade in gastric adenocarcinomas. World J Gastroenterol (2010) 0.78
The paradox role of caspase cascade in ionizing radiation therapy. J Biomed Sci (2016) 0.77
Effects of prostaglandin E2 on p53 mRNA transcription and p53 mutagenesis during T-cell-independent human B-cell clonal expansion. FASEB J (2013) 0.77
EAPP modulates the activity of p21 and Chk2. Cell Cycle (2011) 0.77
Classifying the Progression of Ductal Carcinoma from Single-Cell Sampled Data via Integer Linear Programming: A Case Study. IEEE/ACM Trans Comput Biol Bioinform (2015) 0.77
Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model. Oncogene (2014) 0.77
A p53 axis regulates B cell receptor-triggered, innate immune system-driven B cell clonal expansion. J Immunol (2012) 0.77
Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families. Fam Cancer (2010) 0.77
Identification and characterization of a novel Mdm2 splice variant acutely induced by the chemotherapeutic agents adriamycin and actinomycin D. Cell Cycle (2008) 0.77
Lysophosphatidic Acid Inhibits Apoptosis Induced by Cisplatin in Cervical Cancer Cells. Biomed Res Int (2015) 0.77
p53 increase mitochondrial copy number via up-regulation of mitochondrial transcription factor A in colorectal cancer. Oncotarget (2016) 0.76
TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells. J Immunol (2015) 0.76
ALDH3A1 Plays a Functional Role in Maintenance of Corneal Epithelial Homeostasis. PLoS One (2016) 0.75
Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. Cancer Res (2016) 0.75
Jobelyn® Supplement Lowered Neuronal Degeneration: Significance of Altered p53 and ɤ-Enolase Protein Expressions in Prefrontal Cortex of Rat Exposed to Ethanol. Ann Neurosci (2016) 0.75
Immunohistochemistry Study of P53 and C-erbB-2 Expression in Trophoblastic Tissue and Their Predictive Values in Diagnosing Malignant Progression of Simple Molar Pregnancy. Iran J Cancer Prev (2016) 0.75
MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation. Oncogene (2016) 0.75
CHFR negatively regulates SIRT1 activity upon oxidative stress. Sci Rep (2016) 0.75
Impact of MDM2 309T>G polymorphism on sarcomagenesis. Int J Clin Exp Med (2015) 0.75
Molecular characterization of TP53 gene in human populations exposed to low-dose ionizing radiation. Biomed Res Int (2013) 0.75
[Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer]. Pathologe (2008) 0.75
Characterization of the new human pleomorphic undifferentiated sarcoma TP53-null cell line mfh-val2. Cytotechnology (2017) 0.75
Potential malignant transformation in the gastric mucosa of immunodeficient mice with persistent Mycoplasma penetrans infection. PLoS One (2017) 0.75
The hallmarks of aging. Cell (2013) 14.29
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Cellular senescence in cancer and aging. Cell (2007) 9.04
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature (2009) 7.96
The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature (2009) 7.39
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A (2008) 5.21
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell (2009) 4.59
The common biology of cancer and ageing. Nature (2007) 4.28
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J (2002) 4.17
Delayed ageing through damage protection by the Arf/p53 pathway. Nature (2007) 3.87
Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab (2006) 3.22
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun (2010) 2.97
The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer (2006) 2.85
Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell (2008) 2.85
Programmed cell senescence during mammalian embryonic development. Cell (2013) 2.78
The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell (2004) 2.65
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature (2006) 2.51
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47
Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature (2013) 2.47
Epigenetic regulation of Nanog expression by Ezh2 in pluripotent stem cells. Cell Cycle (2011) 2.45
A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol (2008) 2.43
Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway. Cell Cycle (2010) 2.41
A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle (2011) 2.13
SIRT1: recent lessons from mouse models. Nat Rev Cancer (2010) 2.07
Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res (2007) 1.97
miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle (2010) 1.95
Tumour biology: Policing of oncogene activity by p53. Nature (2006) 1.86
Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab (2012) 1.81
Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev (2004) 1.71
IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int (2012) 1.59
Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J Am Soc Nephrol (2009) 1.57
Oncogenicity of the developmental transcription factor Sox9. Cancer Res (2012) 1.55
Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens (2005) 1.53
A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol (2008) 1.51
Mechanistic principles of chromatin remodeling guided by siRNAs and miRNAs. Cell Cycle (2008) 1.50
Sirtuin 1 regulation of developmental genes during differentiation of stem cells. Proc Natl Acad Sci U S A (2010) 1.48
Polycomb mediated epigenetic silencing and replication timing at the INK4a/ARF locus during senescence. PLoS One (2009) 1.48
SIRT1 contributes to telomere maintenance and augments global homologous recombination. J Cell Biol (2010) 1.48
Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res (2007) 1.45
WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res (2009) 1.39
The Arf/p53 pathway in cancer and aging. Cancer Res (2008) 1.37
Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep (2005) 1.36
Genome-wide CTCF distribution in vertebrates defines equivalent sites that aid the identification of disease-associated genes. Nat Struct Mol Biol (2011) 1.31
Increased p53 activity does not accelerate telomere-driven ageing. EMBO Rep (2006) 1.30
Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J (2008) 1.25
Genetic inactivation of Par4 results in hyperactivation of NF-kappaB and impairment of JNK and p38. EMBO Rep (2003) 1.24
p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation. Cell Stem Cell (2012) 1.23
Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS One (2009) 1.22
Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. Mol Cell Biol (2009) 1.20
PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab (2012) 1.18
p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol (2010) 1.18
The absence of p53 is critical for the induction of apoptosis by 5-aza-2'-deoxycytidine. Oncogene (2004) 1.18
Resistance to viral infection of super p53 mice. Oncogene (2005) 1.17
Dietary restriction: standing up for sirtuins. Science (2010) 1.17
Activation of cyclin D1-kinase in murine fibroblasts lacking both p21(Cip1) and p27(Kip1). Oncogene (2002) 1.15
Impact of Sirt1 on mammalian aging. Aging (Albany NY) (2010) 1.13
Anti-aging activity of the Ink4/Arf locus. Aging Cell (2009) 1.13
Cellular senescence limits regenerative capacity and allograft survival. J Am Soc Nephrol (2012) 1.11
EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep (2012) 1.10
The senescent side of tumor suppression. Cell Cycle (2005) 1.08
Crosstalk between PKCzeta and the IL4/Stat6 pathway during T-cell-mediated hepatitis. EMBO J (2004) 1.07
In vivo inhibition of c-MYC in myeloid cells impairs tumor-associated macrophage maturation and pro-tumoral activities. PLoS One (2012) 1.06
Dissecting the role of mTOR complexes in cellular senescence. Cell Cycle (2012) 1.05
Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res (2005) 1.04
Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer. Cancer Res (2013) 1.04
Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma. Proc Natl Acad Sci U S A (2009) 1.02
A high-throughput loss-of-function screening identifies novel p53 regulators. Cell Cycle (2006) 1.02
Antiviral action of the tumor suppressor ARF. EMBO J (2006) 1.02
Regulation of mature T lymphocyte proliferation and differentiation by Par-4. EMBO J (2003) 0.99
Genomic instability in iPS: time for a break. EMBO J (2011) 0.99
A new mechanism of inactivation of the INK4/ARF locus. Cell Cycle (2006) 0.98
p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Res (2005) 0.96
SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. Hepatology (2014) 0.96
Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp Cell Res (2002) 0.95
NOTCH pathway inactivation promotes bladder cancer progression. J Clin Invest (2015) 0.95
Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency. Aging Cell (2011) 0.95
Shifting senescence into quiescence by turning up p53. Cell Cycle (2010) 0.93
Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. Cardiovasc Res (2007) 0.92
Regulation of the INK4a/ARF locus by histone deacetylase inhibitors. J Biol Chem (2005) 0.92
Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens (2005) 0.91
Ribosomal stress induces L11- and p53-dependent apoptosis in mouse pluripotent stem cells. Cell Cycle (2012) 0.91
The PTEN/NRF2 axis promotes human carcinogenesis. Antioxid Redox Signal (2014) 0.90
Regulation of macrophage activation and septic shock susceptibility via p21(WAF1/CIP1). Eur J Immunol (2009) 0.90
Tumor suppressor p53 mediates apoptotic cell death triggered by cyclosporin A. J Biol Chem (2002) 0.90
SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53. PLoS One (2010) 0.89
Impact papers on aging in 2009. Aging (Albany NY) (2010) 0.89
Epigenetic induction of the Ink4a/Arf locus prevents Schwann cell overproliferation during nerve regeneration and after tumorigenic challenge. Brain (2013) 0.89
Growth inhibition by the tumor suppressor p33ING1 in immortalized and primary cells: involvement of two silencing domains and effect of Ras. Mol Cell Biol (2005) 0.88
Specific contribution of p19(ARF) to nitric oxide-dependent apoptosis. J Immunol (2006) 0.88
A strategy to study tyrosinase transgenes in mouse melanocytes. BMC Cell Biol (2005) 0.88
Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2. Oncogene (2002) 0.88
Genomic profiling of circulating plasma RNA for the analysis of cancer. Clin Chem (2007) 0.88
The p21(Cip1) protein, a cyclin inhibitor, regulates the levels and the intracellular localization of CDC25A in mice regenerating livers. Hepatology (2002) 0.88
MSK2 inhibits p53 activity in the absence of stress. Sci Signal (2009) 0.87
Different cooperating effect of p21 or p27 deficiency in combination with INK4a/ARF deletion in mice. Oncogene (2004) 0.86
Social support systems as determinants of self-management and quality of life of people with diabetes across Europe: study protocol for an observational study. Health Qual Life Outcomes (2014) 0.86